The Walden Group Represented Total Titanium, Inc in Its Sale to a Subsidiary of Bausch + Lomb Corporation

The Walden Group is pleased to announce that it represented Total Titanium, Inc. (TTI) in its sale to a subsidiary of Bausch + Lomb Corporation (NYSE/TSX:BLCO) (“Bausch + Lomb”). TTI was one of the last remaining independently-owned manufacturers of precision ophthalmic instruments based in the United States. Bausch + Lomb is a leading global eye health company dedicated to helping people see better to live better.

As an extremely high-end innovative OEM manufacturer, TTI developed efficient, high-precision Swiss-lathe production processes and finishing operations that optimize accuracy, quality, regulatory compliance, speed-of-execution, and customer satisfaction. Vertically integrated and forward-looking, TTI created sophisticated training and apprenticeship programs to enable a continual progression of expert instrument makers and other craftspeople.

Walden guided TTI and its principals in developing corporate analytics and presentations and interacting with many parties in coming to terms with a transaction with Bausch + Lomb. The transaction is expected to add value to Bausch + Lomb, its customers, ophthalmic surgeons and their patients. It is also expected to support productive growth in the TTI business, enable TTI to provide even better service to its OEM accounts and enhance professional development of its loyal and talented organization.

The Walden Group, Inc.

560 White Plains Rd. I Tarrytown, NY 10591

914 332 9700 / efax 914 303 5043

office@waldenmed.com

www.waldenmed.com